Hepatitis C virus (HCV) infection is a major cause of post-transfusion and community acquired hepatitis, and results in significant morbidity due to chronic hepatitis in an estimated 50-80% of cases. Attempts to control infection with antiviral agents have met with limited success, and the need for an effective vaccine to prevent continued spread of this infection remains paramount. Central to the development of such a vaccine is an understanding of the virus-specific immune responses which confer protection. Cytotoxic T lymphocytes (CTL) have been shown to be an important component of protective immunity in a number of viral infections. CTL may also mediate tissue damage in the infected host under certain conditions, and have been postulated to contribute to liver damage in viral hepatitis. Characterization of the CTL response to HCV is an important step in determining the role of these cells in disease pathogenesis. During the initial period of support provided by AI31563, our laboratory established a method to detect HCV-specific, HLA class I restricted CTL among liver infiltrating lymphocytes from persons with chronic HCV hepatitis. Our initial studies indicate that a) both structural and nonstructural proteins of HCV are targets of CTL in infected persons; b) these CTL are predominantly compartmentalized in the liver i persons with chronic HCV hepatitis; c) the CTL response is HLA class I restricted and directed at multiple 8-10 amino acid epitopes, and can be directed at multiple epitopes simultaneously; d) CTL epitopes exist in regions which tolerate sequence variation. We have recently established method for expanding HCV-specific memory T cells from peripheral blood will allow us to evaluate the CTL response not only in persons in different stages of acute and chronic infection, but will also facilitate longitudinal studies of CTL and their relationship to disease course. Specifically, we propose to a) Evaluate liver biopsy-derived lymphocytes and peripheral blood lymphocytes from HCV-seropositive persons with symptomatic and asymptomatic chronic HCV infection for the presence of HCV-specific CTL, and characterize the cells mediating this cytotoxicity as well as the dominant viral antigens and epitopes targeted by this response; b) Determine the magnitude and specificity of the HCV-specific CTL response in persons in different stages of infection, including acute infection, chronic infection before and after treatment with interferon, and those with acute flares of hepatitis in order to determine whether a correlation exists between the HCV-specific CTL response and the course of disease; c) Evaluate the potential role of sequence variation as a means of escape from detection by HCV-specific CTL; and d) Determine the HCV-specific CTL response to autologous viruses in infected persons. These studies will provide a detailed understanding of the role of the host cellular immune response in HCV infection, and should facilitate rational vaccine design as well as help to guide immunotherapeutic interventions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI031563-07
Application #
2882171
Study Section
Experimental Virology Study Section (EVR)
Program Officer
Johnson, Leslye D
Project Start
1991-08-01
Project End
2001-02-28
Budget Start
1999-03-01
Budget End
2000-02-29
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Kim, Arthur Y; Kuntzen, Thomas; Timm, Joerg et al. (2011) Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology 140:686-696.e1
Kasprowicz, Victoria; Ward, Scott M; Turner, Alison et al. (2008) Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virus. J Clin Invest 118:1143-53
Kasprowicz, Victoria; Schulze Zur Wiesch, Julian; Kuntzen, Thomas et al. (2008) High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome. J Virol 82:3154-60
Schulze Zur Wiesch, Julian; Lauer, Georg M; Timm, Joerg et al. (2007) Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection. Blood 110:1559-69
Timm, J; Neukamm, M; Kuntzen, T et al. (2007) Characterization of full-length hepatitis C virus genotype 4 sequences. J Viral Hepat 14:330-7
McGovern, Barbara H; Wurcel, Alysse; Kim, Arthur Y et al. (2006) Acute hepatitis C virus infection in incarcerated injection drug users. Clin Infect Dis 42:1663-70
Kim, Arthur Y; Schulze zur Wiesch, Julian; Kuntzen, Thomas et al. (2006) Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med 3:e492
Schulze zur Wiesch, Julian; Lauer, Georg M; Day, Cheryl L et al. (2005) Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol 175:3603-13
Lauer, Georg M; Lucas, Michaela; Timm, Joerg et al. (2005) Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol 79:12979-88
Timm, Joerg; Lauer, Georg M; Kavanagh, Daniel G et al. (2004) CD8 epitope escape and reversion in acute HCV infection. J Exp Med 200:1593-604

Showing the most recent 10 out of 18 publications